The Use of Antidepressants in Pregnancy: Focus on Maternal Risks

被引：11

作者：

Gadot, Yifat ^{[1
]}

Koren, Gideon ^{[1
]}

机构：

[1] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Dept Pediat, Motherisk Program, Toronto, ON, Canada

来源：

JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA | 2015年 / 37卷 / 01期

关键词：

selective serotonin reuptake inhibitor; SSRI; selective norepinephrine reuptake inhibitor; SNRI; depression; risk; pregnancy;

D O I：

10.1016/S1701-2163(15)30364-9

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Studies have consistently reported a decrease in the use of antidepressants during pregnancy compared with the pre-pregnancy period. Multiple recent studies have focused on the potential fetal risks of selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), with very little attention paid to maternal risks. The maternal risks of these medications are the focus of this review. Untreated depression is associated with increased risks of maternal morbidity, both somatic and psychiatric. In contrast, use of antidepressants has been associated with increased risks of hypertension, preeclampsia, and bleeding. In this review we present the evidence for maternal risks in an attempt to develop a risk-benefit ratio.

引用

页码：56 / 63

页数：8

共 112 条

[1]

Abman SH, 1999, PEDIATR PULM, P201

[2]

ACOG Committee on Practice Bulletins--Obstetrics, 2008, Obstet Gynecol, V111, P1001, DOI 10.1097/AOG.0b013e31816fd910

[3]

American College of Obstetrics and Gynecology practice bulletin, 2006, OBSTET GYNECOL, V108, P1039, DOI DOI 10.1097/00006250-200610000-00046

[4] Use of antidepressant medications during pregnancy: a multisite study [J].